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Heart failure (HF) is a rising epidemic due to the ageing population and progress in all areas of medicine. Thus, research efforts are made to ensure a timely diagnosis, to improve prognosis and treatment of the disease and to facilitate risk prediction at the population level. Because of their noninvasive determination with mostly high sensitivity and accuracy, circulating blood biomarkers are becoming increasingly important for daily clinical practice. Natriuretic peptides, especially B-type natriuretic peptide (BNP), N-terminal pro-Btype natriuretic peptide (Nt-proBNP) and midregional pro-atrial natriuretic peptide (MRproANP) and cardiac troponins are established blood biomarkers in HF diagnosis and prognosis of HF-related outcomes. Inflammatory molecules as C-reactive protein (CRP) may have added value in anti-inflammatory therapy guidance. Next-generation biomarkers including soluble source of tumorigenicity 2 (sST2), growth differentiation factor-15 (GDF-15), galectin-3 (Gal-3) and diverse microribonucleic acids (miRNAs) may have addi
Introduction
Heart failure (HF) is a growing epidemic related to significant morbidity and mortality. The prevalence of the disease continuously increases due to the ageing population and success in treating cardiovascular diseases that often precede HF. A further relevant increase by nearly 50% is predicted until 2030, leading to a rising socioeconomic challenge with an explosion of costs in the next decades [1] . Lifetime risk of HF is still high with 20-45% and strongly age-dependent [2] . HF hospitalization rates declined substantially over time; however, 1-year mortality due to HF did not significantly improve [3] . According to the National Center of Health Statistics (https://www.cdc.gov/nchs/da ta_access/vitalstatsonline.htm), one of eight deaths is related to HF.
Structural or functional alterations in the heart lead to reduced cardiac output and rising intracardiac pressures. The resulting HF syndrome comprises typical symptoms such as dyspnoea, ankle swelling and fatigue [4] . Current guidelines classify three HF subtypes: HF with preserved (HFpEF), mildly reduced (HFmrEF) and reduced ejection fraction (HFrEF) [4] . The proportion of HFpEF seems to be slightly lower than that of HFrEF [5] . In more advanced stages of the disease mirrored by the severity of clinical symptoms, survival is poor [6] and independent of left ventricular ejection fraction (LVEF) [7] .
Hence, there is an increasing need for structured screening, early diagnosis and improved management of HF. Biomarkers have progressively attracted the researchers' interest, as they facilitate noninvasively the identification of patients at risk. Furthermore, biomarkers provide important information about HF severity and may support therapy guidance and risk stratification. The clinical use of biomarkers is recommended in current HF guidelines [4, 8] indicating their rising importance in the entire field of HF.
A biomarker is defined as an objectively measured indicator of normal biological or pathological processes or pharmacological responses to therapeutic interventions [9] . A generally useful biomarker should have a high sensitivity and specificity, and its determination should be reproducible, standardized and cost-effective. Although specific proteins (proteomics), genetic variants (genomics), metabolic processes (metabolomics) or imaging techniques (radiomics) may fulfil the biomarker definition, this Review focuses on circulating blood biomarkers ( Fig. 1) . We discuss established and novel biomarkers in the context of HF diagnosis, prognosis and risk stratification in both, population and diseased cohorts.
Established biomarkers in clinical practice

B-type natriuretic peptide and N-terminal B-type natriuretic peptide
Natriuretic peptides are the gold standard markers in the diagnosis and prognosis of HF (Table 1) . The proteolytic cleavage of the prohormone pro-B-type natriuretic peptide (proBNP) produces equimolar amounts of the C-terminal, physiologically active BNP and the inactive N-terminal proBNP (Nt-proBNP). Both are secreted directly from the LV myocardium in response to end-diastolic wall stress through volume and pressure overload [10, 11] (Fig. 2) . BNP is a vasoactive hormone involved in volume homeostasis, vasodilation and cardiovascular remodeling [12] . The effects are concentration-dependent. Lower concentrations (1.5-fold to threefold) stimulate natriuresis, and higher levels (20-fold) increase renal blood flow and glomerular filtration rate.
Importance of BNP and Nt-proBNP in HF diagnosis
In the presence of HF symptoms, the determination of natriuretic peptides is recommended by current guidelines [4] . Concentrations of ≤35 pg mL
À1
(BNP) or ≤125 pg mL À1 (Nt-proBNP) in the nonacute setting, and levels of <100 pg mL À1 (BNP) or <300 pg mL À1 (Nt-proBNP) in the acute setting, safely and easily rule out suspected HF with a high negative predictive value of 94% and 98%, respectively [4] . Although released in a 1 : 1 ratio and equally cleared by the kidneys, circulating levels of Nt-proBNP are higher than those of BNP. This is explained by the longer half-life of Nt-proBNP compared to BNP (120 h vs. 20 min) [13] . BNP and Nt-proBNP levels rise with increasing age. Therefore, age-related cut-offs have been discussed [14] . The difficulty to identify concentrations with a clinically appropriate high positive predictive value is explained by various clinical conditions which lead to BNP and Nt-proBNP rise irrespective of HF syndrome. Natriuretic peptides are, beyond others, increased in acute coronary syndrome (ACS), mitral regurgitation, atrial fibrillation, pulmonary hypertension or embolism, chronic obstructive pulmonary disease (COPD) with cor pulmonale and each form of increased cardiac output (sepsis, hyperthyreosis and takotsubo cardiomyopathy). In contrast, a decrease in natriuretic peptides was reported with increasing body mass index [15] . Patients after weight loss through bariatric surgery showed a significant increase in BNP levels [16] . Of clinical importance, clearance of BNP, but not NtproBNP, is mediated by neprilysin, which results in higher BNP levels under neprilysin inhibition via sacubitril/valsartan (Entresto â ) [17] , which is Table 1 Importance of cardiac biomarkers in heart failure diagnosis, outcomes, therapy guidance and additional benefit at the population level.
Heart failure diagnosis Heart failure-related outcomes Heart failure therapy guidance
Risk prediction
BNP, B-type natriuretic peptide; CRP, C-reactive protein; GDF-15, growth differentiation factor-15; hs, high-sensitivity; miRNA, microribonucleic acid; MR-proANP, midregional pro-atrial natriuretic peptide; Nt-proBNP, N-terminal pro-B-type natriuretic peptide; sST2, soluble source of tumorigenicity 2. ++ useful/advised, + maybe useful (no or conflicting evidence), --not useful, -maybe not useful (no or conflicting evidence). increasingly used in HF therapy. However, the exact increase in BNP concentration and its durability is still not clear.
In dyspnoeic patients presented to the emergency department included in the 'Breathing Not Properly' study, BNP diagnosed HF with a sensitivity of 90%, a specificity of 76% and an accuracy of 83% at a cut-off of 100 pg mL À1 for differentiating congestive HF from other causes of dyspnoea [18] . Nt-proBNP had an even higher sensitivity for excluding HF with a negative predictive value of 99% at a cut-off of 300 pg mL À1 [19] . Diagnosis of HFpEF is still challenging and mainly based on clinical presentation. However, current guidelines require elevated natriuretic peptides for HFpEF diagnosis [4] . Noteworthy, Nt-proBNP levels are higher in HFrEF compared to HFpEF, because of much lower end-diastolic wall stress and thus lower stimulus for BNP production in HFpEF [20] . Further emerging biomarkers as soluble source of tumorigenicity 2 (sST2), galectin-3 (Gal-3) and matrix metalloproteinases that facilitate diagnosis and understanding of HFpEF pathophysiology are under current research.
Value of BNP and Nt-proBNP in HF prognosis Besides their importance in ruling out HF, natriuretic peptides are potent markers to assess prognosis of HF patients (Table 1) . In prospectively analysed patients with stable angina, BNP levels were significantly increased in patients with future cardiovascular events, even after multivariable adjustment [21] . This clearly shows that BNP provides additional prognostic information beyond the classical cardiovascular risk factors. A higher percentage of time in biomarker response (Nt-proBNP <1000 pg mL À1 ) was associated with lower event rates in 151 HFrEF patients of the 'ProBNP Outpatient Tailored Chronic Heart Failure' (PROTECT) study [22] . BNP was shown to predict cardiovascular and all-cause mortality independent of age, NYHA state, previous myocardial infarction and LVEF [23] . Among >48 000 acute decompensated HFpEF and HFrEF patients of the 'Acute Decompensated Heart Failure National Registry' (ADHERE), the authors found a nearly linear relationship between BNP quartiles at admission and in-hospital mortality (1.9% in the lowest quartile compared to 6% in the highest quartile) [24] . Discharge BNP concentrations were strong predictors for 30-day readmission and 1-year mortality [25] . After hospitalization for acute HF, predischarge Nt-proBNP levels were shown to provide independent useful prognostic value, whereas admission plasma Nt-proBNP was not predictive [26] .
However, natriuretic peptides do not only predict outcome of HF itself, but also that of HF comorbidities. Elevated natriuretic peptides due to pulmonary hypertension or embolism were related to RV dysfunction associated with poor prognosis independently of LV function [20] . In patients with acute exacerbated COPD, elevated Nt-proBNP at discharge was shown to be an independent predictor of rehospitalization and mortality [27] .
Evidence of BNP and Nt-proBNP in HF therapy guidance There is conflicting evidence that natriuretic peptide-guided therapy improves HF outcome (Table 1 ). In the Canadian 'The Improved Management of Patients With Congestive Heart Failure' (IMPROVE-HF) study, the sole knowledge of NtproBNP in patients with suspected acute HF was shown to reduce the length of stay in the emergency department, rehospitalization and related costs in the outpatient sector [28] . The Stars BNP study proved that patients titrated with the aim to achieve target BNP plasma levels <100 pg mL À1 had a shorter in-hospital stay and a higher event-free survival compared to the control group with usual care [29] . In line, the PROTECT study showed that the Nt-proBNP-guided study group had an improved quality of life and a significantly lower rate of cardiovascular events compared to the control group [30] . However, several studies produced conflicting results. The 'Can Pro-Brain-Natriuretic Peptide Guided Therapy of Chronic HF Improve Heart Failure Morbidity and Mortality?' (PRIMA) trial failed to show a clinical benefit of a natriuretic peptideadjusted HF therapy [31] . The 'Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure' (GUIDE-IT) trial on high-risk HFrEF patients with a target Nt-proBNP level of <1000 pg mL À1 was terminated prematurely, as the Nt-proBNP-guided strategy did not result in an improvement of cardiovascular death or HF hospitalization compared to usual care [32] . In another study on older individuals, the Nt-proBNP arm showed a higher survival free of HF hospitalization, but not any hospitalization, compared to the clinically guided arm [33] . Both treatment strategies improved symptoms and quality of life and reduced BNP levels similarly over time, although these effects tended to be lower in patients aged ≥75 years. Although slightly more serious adverse events occurred in older patients [33] , Nt-proBNP-guided HF therapy was proven to be cost-effective in HFrEF patients, most pronounced in patients <75 years or with <2 comorbidities [34] . In most of these studies, patients under biomarker guidance had higher doses of HF-specific therapy, especially ACE inhibitors and beta-blockers. Hence, natriuretic peptideguided therapy seems to be a useful means to achieve optimal doses of guideline-recommended HF medication, although there is yet no clear advice of biomarker-guided therapy for improving HF outcomes. The attempt to use a synthetically produced BNP, nesiritide, showed no effect on dyspnoea, rehospitalization for HF or all-cause mortality at 30 days [35] .
Usefulness of BNP and Nt-proBNP in risk stratification in the community Natriuretic peptides serve as potent risk predictors in the community setting (Table 1) . In outpatient care patients at HF risk, BNP-based screening reduced the combined rates of LV systolic dysfunction, diastolic dysfunction and HF [36] . The Cardiovascular Health Study showed that individuals with Nt-proBNP levels in the highest quintiles were at greater risk of HF and cardiovascular death compared to those in the lowest quintile [37] . In the Dallas Heart Study, participants without clinical HF, but who were diagnosed with LV hypertrophy (LVH), had a >4-fold higher risk for HF and cardiovascular death once they had measurable NtproBNP levels compared to those without LVH and in-range Nt-proBNP concentrations [38] .
Meaning of change in BNP and Nt-proBNP and outcome The change in natriuretic peptide levels and time of measurement seems to be important for risk prediction. Community-based older adults without HF at baseline and with initially low concentrations of Nt-proBNP and troponin T (TnT) were found to be at greater risk for systolic dysfunction, incident HF and cardiovascular death, once both biomarkers increased over time [39] . In >2900 participants of the Cardiovascular Health Study free of HF, physical activity could reduce the likelihood for an increase in Nt-proBNP and high-sensitivity (hs)TnT, and a higher activity was related to a lower long-term HF incidence [40] . Change in Nt-proBNP levels during HF hospitalization seems to be a strong predictor for rehospitalization and death within 6 months [41] . Further data demonstrated that each 100 pg mL À1 increase in BNP is associated with a 35% increase in relative mortality risk [42] .
To summarize, HF can easily be ruled out considering the respective natriuretic peptide cut-offs in the acute and nonacute setting. BNP and Nt-proBNP are useful in the assessment of HF prognosis and serve as risk predictors at the population level. Despite conflicting evidence, BNP and Nt-proBNP might be valuable in HF therapy guidance.
Midregional pro-atrial natriuretic peptide
Atrial natriuretic peptide (ANP) is a hormone secreted by atrial cardiomyocytes due to volume overload and wall stress [43] (Fig. 2) . In HF, ANP is also released by ventricular cardiomyocytes. Cleavage of the precursor proANP results in the more stable midregional proANP (MR-proANP).
Clinical relevance of MR-proANP in HF diagnosis
Next to BNP and Nt-proBNP, MR-proANP seems to be the sole biomarker usable for HF diagnosis (Table 1) . However, there is conflicting evidence in the reliability of MR-proANP in diagnosing the disease. Seronde et al. demonstrated that MRproANP performed less well in HF diagnosis compared to established natriuretic peptides [44] . Another study, which prospectively evaluated dyspnoeic patients in the emergency department, attested MR-proANP a high negative predictive value in HF exclusion with a sensitivity of 91.1% at a cut-off of 120 pmol L À1 [45] . In line, current HF guidelines recommend the determination of MR-proANP in the acute setting, whereas concentrations <120 pmol L À1 are able to rule out HF [4] .
Evidence of MR-proANP in HF risk prediction and outcomes A better long-term prognostic value of MR-proANP compared to proBNP, BNP and Nt-proBNP has been discussed [44] . In patients with chronic HF of the 'Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca' (GISSI-HF) trial, the addition of MR-proANP to a model containing clinical risk factors and/or Nt-proBNP improved the net reclassification for mortality [46] . In highrisk patients with stable cardiovascular disease, the addition of MR-proANP to a traditional risk model showed a modest but statistically significant improvement in prognostication of major cardiovascular events [47] .
Thus, MR-proANP displays a distinct alternative to BNP and Nt-proBNP in HF diagnosis, although this novel biomarker is not yet routinely used in clinical
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Cardiac troponin
In HF, deficient oxygen supply results in subendocardial ischaemia and release of myofibrillar proteins such as TnI/TnT. This troponin release is fully unrelated to any coronary origin [48] ( Fig. 2) . Cardiac troponins are regulatory proteins controlling the calcium-mediated interaction of actin and myosin during myocyte contraction. Whereas TnI is heart-specific, TnT is expressed to a minor extent in skeletal muscle cells [49] . The advent of hs-Tn assays improved the diagnostic accuracy, and their application in clinical routine enhanced clinical decision-making as well as cost-effectiveness [50] .
Importance of TnI and TnT in HF diagnosis
Apart from their excellent diagnostic performance in patients with suspicion of ACS, cardiac troponins are negligible in the diagnosis of HF (Table 1) . In contrast to BNP and Nt-proBNP, (hs-)TnI/TnT below the respective cut-offs cannot rule out HF. In acute HF, clinical presentation is equal to that of ACS.
Here, dynamics of hs-TnI/TnT is mandatory to differentiate between both syndromes, but the change in troponin concentrations over 1 to even 6 h in HF is very small in contrast to patients with ACS.
Relation of TnI and TnT to cardiovascular outcomes Positive cardiac troponin was associated with poor haemodynamics, particularly with lower cardiac indexes and lower LVEF [51] and progressive decline in LVEF over time [52] . In >3600 patients with stable coronary artery disease and preserved LVEF, even very low hs-TnI levels were associated with HF and cardiovascular death [53] (Table 1) . In advanced HF patients, detectable TnI used in combination with BNP was shown to be a useful marker to identify HF patients at increased mortality risk [52] . Noteworthy, a dose-response relation between TnI concentration and mortality has been discussed [54] . In the ADHERE registry, acute decompensated HF patients with positive troponin (N = 4.240, either TnI >1.0 lg L À1 or TnT >0.1 lg L
À1
) at admission had a >2.5-fold higher in-hospital mortality than those who were troponin negative [51] . In patients with type 2 diabetes and stable coronary artery disease, baseline TnT above the upper limit of normal was associated with approximately a doubling in risk of myocardial infarction, stroke, HF and cardiovascular and all-cause mortality [55] .
TnI and TnT and risk prediction at the population level In population-based cohorts, cardiac troponin is related to incident HF as well as other cardiovascular outcomes (Table 1 ). In the Dallas Heart Study, higher TnT levels were associated with congestive HF, LVH, diabetes mellitus and chronic kidney disease [56] . In the 'Atherosclerosis Risk in Communities' (ARIC) study, middle-aged to older adults without cardiovascular disease having hsTnT in the highest categories had an approximately sixfold increased HF risk [57] . In addition, the ARIC study showed that individuals with severe obesity and high hs-TnT levels had a more than ninefold higher risk of incident HF than individuals with normal weight and undetectable hs-TnT [58] . Risk prediction could be improved for coronary artery disease, mortality and incident HF when TnT or NtproBNP was added to traditional risk factors [57] . Population-based older adults with detectable TnT or increased Nt-proBNP were at higher risk for allcause mortality and cardiovascular death. Those with both, elevated Nt-proBNP and detectable TnT, showed even worse survival [59] .
Change in cardiac troponins and outcome Similar to natriuretic peptides, increase or decrease in cardiac troponins over time predicts incident HF better than the baseline values. Increasing TnI, measured at admission, discharge and up to 4 consecutive days during hospitalization for acute HF, was associated with increased mortality compared to stable or decreasing TnI [60] . One-year mortality and hospital readmission were significantly higher for decompensated HF patients with persistently elevated TnT levels (>0.02 ng mL À1 ) compared to those whose levels decreased [61] . In line, in patients with dilated cardiomyopathy, a decrease in TnT over time was associated with a decrease in LV diastolic dimension, an increase in LVEF and a better prognosis than persistent TnT elevation [62] . Serial measures of hs-TnT in patients with chronic HF in the 'Valsartan Heart Failure Trial' (Val-HeFT) and the GISSI-HF trial showed that changes in hs-TnT concentrations over time were associated with HF severity and progression [46] . Serial measurements seem to have a more robust prognostic value than a single determination of cardiac troponins. to HF course and different cardiovascular outcomes.
C-reactive protein
Acute-phase responses (i.e. acute COPD exacerbation) often trigger decompensation of chronic HF. In turn, during HF, the immune system is chronically and measurably activated (Fig. 2) . Thus, inflammatory biomarkers are supposed to be involved in the pathogenesis of worsening HF [63] . There is evidence that mesenteric hypoperfusion during acute HF results in bacterial or endotoxin translocation from the bowel into the bloodstream, which supports a correlation of HF severity and the extent of inflammatory response [64, 65] .
C-reactive protein (CRP) is a member of the pentraxin family and mainly produced in the liver as response to systemic inflammation processes.
CRP and HF severity
Although CRP is not usable for HF diagnosis (Table 1) , it is associated with clinical HF presentation. In the Val-HeFT trial, elevated CRP levels were related to signs of more severe HF such as NYHA classes III or IV or lower LVEF [66] . In contrast, the prospective 'Serial Biomarker Measurements and New Echocardiographic Techniques in Chronic Heart Failure Patients Result in Tailored Prediction of Prognosis' (Bio-SHiFT) study examining stable outpatients with chronic HF found no association between repeatedly assessed CRP and NYHA class [67] .
Usefulness of CRP in anti-inflammatory therapy guidance
The importance of chronic immune activation and consecutive inflammation quantified by moderately elevated CRP levels (3-10 mg L À1 ) in acute HF may help to guide anti-inflammatory therapies (Table  1) , such as statins. In the retrospective 'Controlled Rosuvastatin Multinational Trial in Heart Failure' (CORONA) study, administration of rosuvastatin in patients with ischaemic systolic HF and hs-CRP ≥2.0 mg L À1 was associated with better outcomes [68] . Similarly, patients with ACS treated to achieve a LDL target <70 mg dL À1 and hs-CRP <2 mg L
À1
had better outcomes than patients in whom only one target was reached [69] .
CRP and HF outcomes
Elevated CRP levels have consequently been related to worse outcomes (Table 1) , while a specific cut-off seems to play a role in the association of CRP and HFrelated outcomes. In acute HF, Minami et al. stated a cut-off >11.8 mg L À1 [63] , which is consistent with prior studies [70, 71] . Alonso-Martinez et al. showed that patients hospitalized for acute HF with CRP levels >9 mg L À1 had higher readmission rates and shorter periods before readmission [70] . In another study, patients with elevated CRP (>10 mg L À1 ) on admission had an almost twofold higher 1-year mortality risk [71] . In line, Minami et al. showed that CRP levels in the highest tertile (>11.8 mg L À1 ) within 120 days after admission were independently associated with higher all-cause, cardiac and noncardiac deaths in acute decompensated HF patients without obvious, severe infections [63] . Surprisingly, CRP is a good predictor of adverse outcomes in uninfected, but not in infected patients [72] . In addition, serial measured CRP was shown to associate well with different HF-related outcomes [67] .
Overall, although elevated CRP concentrations mirror inflammatory conditions related to poor HF outcomes, CRP is not sufficiently specific to be a useful biomarker in clinical HF management.
Next-generation biomarkers under research
A number of novel biomarkers are clinically available but not routinely used yet. However, they provide, on top of already known biomarkers, additional information in terms of diagnosis, severity and prognosis of HF.
Soluble source of tumorigenicity 2
Source of tumorigenicity 2 (ST2) is a member of the interleukin (IL)-1 cytokine receptor superfamily and exists in both, membrane-bound and soluble forms. Both are receptors for the inflammatory cytokine IL-33. IL-33 exerts protective cardiovascular effects, including reduced atherosclerotic burden [73] , and reduced cardiac hypertrophy and fibrosis in a murine model of pressure overload [74] . The soluble form of ST2, sST2, prevents binding of IL-33 to membrane-bound ST2 (Fig. 2) , resulting in tissue fibrosis, reduced cardiac function and accelerated disease progression [75] . In line, ablation of IL-33 in mice led to exacerbated LVH, increased cardiac chamber dilation, aggravated fibrosis and impaired cardiac function [76] .
Importance of sST2 for HF diagnosis Although sST2 levels are higher in patients with compared to those without HF, this biomarker is Blood biomarkers and heart failure / C. Magnussen & S. Blankenberg not useful to diagnose HF (Table 1) . In dyspnoeic patients, Nt-proBNP was shown to be superior to sST2 for the diagnosis of acute HF [77] . However, sST2 was independently related to poor functional status, [78] and combination of Nt-proBNP and sST2 gave further information about NYHA states [79] . Although sST2 levels are higher in HFrEF than in HFpEF patients, Wang et al. described sST2 as relatively better than Nt-proBNP in the detection of HFpEF in hypertensive patients [79] .
Relation of sST2 and cardiac structural changes In the 'Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study' (EPHESUS) [80] , sST2 levels were good surrogates of LV remodeling. Among dyspnoeic patients with and without acute HF, sST2 concentrations associated well with RV systolic pressure, LV diameters and LVEF [81] . In patients with LV systolic dysfunction after acute myocardial infarction, sST2 levels were positively associated with the change in infarct volume index and might thus be useful in the prediction of medium-term LV functional recovery [82] .
sST2 and HF prognosis
In dyspnoeic patients, sST2 concentrations were strongly predictive of mortality [77, 81] . In line, increased sST2 concentrations independently predicted 1-year all-cause mortality in acute HF patients [83] . After myocardial infarction, elevated sST2 values were associated with increased risk of HF and death [84] . Although baseline sST2 levels, which were mostly in the normal range, did not provide substantial prognostic information in HFrEF, an increase in sST2 within 12 months was associated with higher risk of poor outcomes [85] . This suggests that repeat measurements of sST2 may be reasonable for HF risk prediction (Table 1) . Noticeably, the prognostic value of sST2 is not influenced by renal insufficiency [86] , a common comorbidity in HF patients.
Evidence of sST2 in population studies
A substudy of the Framingham Heart Study could not relate sST2 to echocardiographic measures [80] . In contrast, sST2 appeared to be strongly associated with the presence of diastolic dysfunction in the Cardiovascular Health Study [80] . In a Finish population, sST2 could not show an improvement in longterm prediction of HF or all-cause mortality [87] .
In summary, although sST2 has no clinical evidence in the diagnosis of HF, it seems to be a good marker of cardiac remodeling. Although there is evidence that sST2 might serve to predict HFrelated outcomes in dyspnoeic or acute HF patients, there is still no clear benefit for risk prediction at the population level.
Growth differentiation factor-15
Growth differentiation factor-15 (GDF-15), which is also known as serum macrophage inhibitory cytokine-1 (MIC-1), is a protein belonging to the transforming growth factor beta superfamily. GDF-15 is a marker of cell injury and inflammation (Fig. 2) . In physiological state, the highest amount of GDF-15 is expressed in the placenta. An increase in blood concentrations is associated with diverse pathological conditions, including atherosclerosis and chronic HF [88] .
Relation of GDF-15 to HF syndrome Elevated GDF-15 levels are significantly related to NYHA class, LVEF and Nt-proBNP [89] . In obese individuals with normal LVEF, GDF-15 showed better correlation with LV diastolic dysfunction than Nt-proBNP [90] . In HFrEF patients, higher GDF-15 concentrations were associated with more severe HF states.
GDF-15 and risk prediction
In chronic HFrEF, GDF-15 served as a significant predictor for all-cause mortality [91] (Table 1) even after multivariable adjustment for demographic factors and established biomarkers as hs-TnT and Nt-proBNP [92] . GDF-15 was shown to independently predict death or first HF rehospitalization in both HF subtypes even after adjusting for important clinical predictors including hs-TnT and Nt-proBNP [93] .
In individuals from the general population without previous cardiovascular events, addition of GDF-15 to traditional risk factors and echocardiographic measurements provided significant improvement in risk prediction [94] .
To conclude, GDF-15 is a strong predictor of allcause mortality without further benefit in HF diagnosis or disease-specific outcomes.
expression is increased in activated macrophages (Fig. 2) , which induces cardiac fibroblast proliferation, collagen deposition and ventricular dysfunction [96] . Experimental research has shown that Gal-3 directly induces pathologic remodeling of the heart and is therefore considered a culprit protein in the development of cardiac fibrosis in HF [97] . Pharmacological inhibition of Gal-3 attenuates cardiac fibrosis, LV dysfunction and consecutive HF [98] . In patients with chronic HF, elevated Gal-3 levels indicated more severe HF [99] .
Gal-3 and HF prognosis
In HFrEF patients, an increase in Gal-3 over time, but not baseline Gal-3, was associated with HF hospitalization and all-cause mortality [99] ( Table 1 ). The predictive value of Gal-3 was shown to be even stronger in HFpEF compared to HFrEF patients [100] . In acute HF, elevated Gal-3 concentrations predicted cardiovascular events 1 year after hospitalization for acute HF [101] . High levels of Gal-3 (>17.8 ng mL
À1
) at discharge were shown to independently predict early HF rehospitalization [102] and mortality irrespective of echocardiographic markers of HF severity [103] . However, the additive value of Gal-3 to a more conventional risk marker, such as Nt-proBNP, seems to be limited [104] .
At the population level, Gal-3 showed an added predictive value for new-onset HFrEF only in study participants with high cardiovascular risk of the 'Prevention of Vascular and Renal Endstage Disease' (PREVEND) study [105] .
In summary, even if Gal-3 might have a potential benefit in HF subtype classification, its use in clinical HF risk prediction and management is still insufficiently understood.
Microribonucleic acids
Various types of ribonucleic acids (RNAs) can be subclassified according to their mechanism of action, subcellular localization, size and proteincoding potential. Next to messenger RNAs, transfer RNAs and ribosomal RNAs that are involved in protein synthesis, long and short noncoding RNAs regulating gene expression are differentiated. Microribonucleic acids (miRNAs) are part of the short noncoding RNAs [106] .
MiRNAs in HF diagnosis
MiRNAs have recently been described as promising novel HF biomarkers, as altered miRNA expression patterns reflect pathological processes related to HF, such as cardiac fibrosis and hypertrophy [107] (Fig.  2) . MiRNAs as diagnostic biomarkers for HF may be used alone or in combination with BNP. Watson et al. stated five miRNAs (miR-30c, miR-146a, miR-221, miR-328 and miR-375) as potential markers to differentiate between no-HF, HFpEF and HFrEF patients. Addition of age, sex and BNP, separately and in combination, significantly improved diagnostic predictability of all five miRNAs [108] .
Furthermore, miR-423-5p, which is elevated in response to hypertension-induced HF, may be used to monitor treatment efficacy [109] (Table 1) .
MiRNAs and HF-related outcomes
In chronic HF patients from the GISSI-HF trial, miR-132 levels rose with the severity of HF, whereas lower circulating miR-132 levels improved risk prediction for HF readmission, but not for mortality [110] . Bayes-Genis et al. tested 12 miRNAs as predictors for HF hospitalization and all-cause mortality. They demonstrated that higher levels of miR-1254 and miR-1306-5p were significantly associated with the risk of the combined endpoint, although adding these miRNAs to established predictors as age, sex, haemoglobin, renal function and Nt-proBNP did not further improve HF prognostication [111] (Table 1) .
To summarize, although diverse miRNAs may be useful in HF diagnosis and prognosis when added to established biomarkers, their standalone benefit is yet not convincing. 
Multimarker approaches
There is still no widespread clinically available multimarker panel that is able to securely rule-in HF, although the combinational use of established and novel biomarkers was shown to increase the diagnostic accuracy of HF [112] and to improve risk stratification.
Evidence of multimarker approaches in HF prognosis
In patients with chronic HF, a multimarker approach consisting of five biomarkers (including Nt-proBNP, hs-TnT and GDF-15) performed better in prediction of HF-related events than Nt-proBNP alone [113] . The addition of a biomarker panel including BNP, hs-CRP, TnI and renal function markers to a validated clinical HF score significantly improved prediction of adverse events in ambulatory chronic HF patients [114] .
Multimarker panels and risk prediction at the population level
In the 'Biomarkers for Cardiovascular Risk Assessment in Europe' (BiomarCaRE) consortium, 30 biomarkers were tested in the FINRISK 1997 trial, and a biomarker score out of Nt-proBNP, CRP and TnI was validated in the Belfast 'Prospective Epidemiological Study of Myocardial Infarction' (PRIME) study. The score could significantly improve the 10-year risk prediction of cardiovascular events [115] . In the Framingham Heart Study, individuals with a multimarker score composed of sST2, GDF-15 and hs-TnI in the highest quartile, had a sixfold higher incident HF risk and threefold higher risk of death in a 11-year followup with significant net reclassification improvement after adding the score to clinical variables [116] . In line, a panel of six biomarkers (CRP, plasminogen activator inhibitor-1, homocysteine, aldosterone-to-renin ratio, BNP and urinary albumin-to-creatinine ratio) was significantly related to HF risk, whereas BNP emerged as one of the key biomarkers in predicting new-onset HF risk with incremental predictive utility over standard risk factors [117] .
Conclusions
In conclusion, BNP and Nt-proBNP are still the most important circulating biomarkers for HF diagnosis and risk prediction with potential benefit in therapy guidance. MR-proANP has equipotent diagnostic and prognostic capacities; however, MR-proANP is currently not widely used in clinical routine. Cardiac troponins serve as potent risk predictors, and, similarly to B-type natriuretic peptides, concentrations are related to disease severity. CRP, representing an inflammatory component of HF, provides added value in noninfected individuals at risk and serves as a potent risk predictor in clinically apparent HF. Next-generation biomarkers including sST2, GDF-15, Gal-3 and miRNAs, although not yet routinely used in clinical practice, may have added value alone or on top of established biomarkers or clinical variables in HF diagnosis and risk prediction. Multimarker approaches have shown relevant benefit over single biomarkers, but further research is needed to determine the best biomarker combination for HF management. For today's clinical routine, only BNP, Nt-proBNP and MR-proANP should be used in the context of HF diagnosis, prognosis and -in part -therapy monitoring. 
